ArticleJournal of biological engineering2019
Modelling cardiac fibrosis using three-dimensional cardiac microtissues derived from human embryonic stem cells.
Article in Journal of biological engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Label-free mid-infrared dichroism-sensitive photoacoustic microscopy for histostructural analysis of engineered heart tissues.Light, science & applications · 2026Article
- Advancing 3D Engineered In Vitro Models for Heart Failure Research: Key Features and Considerations.Bioengineering (Basel, Switzerland) · 2024Review
- Three-Dimensional iPSC-Based In Vitro Cardiac Models for Biomedical and Pharmaceutical Research Applications.International journal of molecular sciences · 2024Review
- Versatile human cardiac tissues engineered with perfusable heart extracellular microenvironment for biomedical applications.Nature communications · 2024Article
- Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis.Cell regeneration (London, England) · 2023Review
- Biomimetic Cardiac Tissue Models for In Vitro Arrhythmia Studies.Biomimetics (Basel, Switzerland) · 2023Review
- Construction of cardiac fibrosis for biomedical research.Smart medicine · 2023Review
- Biomimetic Electrospun Scaffold-Based In Vitro Model Resembling the Hallmarks of Human Myocardial Fibrotic Tissue.ACS biomaterials science & engineering · 2023Article
- Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues.Frontiers in cardiovascular medicine · 2023Article
- Mechanical response of cardiac microtissues to acute localized injury.American journal of physiology. Heart and circulatory physiology · 2022Article
- Multicellular 3D Models for the Study of Cardiac Fibrosis.International journal of molecular sciences · 2022Review
- A Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development.Current cardiology reports · 2022Review
- Microphysiological stem cell models of the human heart.Materials today. Bio · 2022Review
- A three-dimensional culture system for generating cardiac spheroids composed of cardiomyocytes, endothelial cells, smooth-muscle cells, and cardiac fibroblasts derived from human induced-pluripotent stem cells.Frontiers in bioengineering and biotechnology · 2022Article
- Intersection of stem cell biology and engineering towards next generationFrontiers in bioengineering and biotechnology · 2022Review
- Engineering hiPSC-CM and hiPSC-EC laden 3D nanofibrous splenic hydrogel for improving cardiac function through revascularization and remuscularization in infarcted heart.Bioactive materials · 2021Article
- The NaCellular and molecular life sciences : CMLS · 2021Review
- Cardiac Tissues From Stem Cells: New Routes to Maturation and Cardiac Regeneration.Circulation research · 2021Review
- Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac fibrosis is the most common pathway of many cardiac diseases. To date, there has been no suitable in vitro cardiac fibrosis model that could sufficiently mimic the complex environment of the human heart. Here, a three-dimensional (3D) cardiac sphere platform of contractile cardiac microtissue, composed of human embryonic stem cell (hESC)-derived cardiomyocytes (CMs) and mesenchymal stem cells (MSCs), is presented to better recapitulate the human heart.
resultsWe hypothesized that MSCs would develop an in vitro fibrotic reaction in response to treatment with transforming growth factor-β1 (TGF-β1), a primary inducer of cardiac fibrosis. The addition of MSCs improved sarcomeric organization, electrophysiological properties, and the expression of cardiac-specific genes, suggesting their physiological relevance in the generation of human cardiac microtissue model in vitro. MSCs could also generate fibroblasts within 3D cardiac microtissues and, subsequently, these fibroblasts were transdifferentiated into myofibroblasts by the exogenous addition of TGF-β1. Cardiac microtissues displayed fibrotic features such as the deposition of collagen, the presence of numerous apoptotic CMs and the dissolution of mitochondrial networks. Furthermore, treatment with pro-fibrotic substances demonstrated that this model could reproduce key molecular and cellular fibrotic events.
conclusionsThis highlights the potential of our 3D cardiac microtissues as a valuable tool for manifesting and evaluating the pro-fibrotic effects of various agents, thereby representing an important step forward towards an in vitro system for the prediction of drug-induced cardiac fibrosis and the study of the pathological changes in human cardiac fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.